{"id":"W4415817417","doi":"10.1007/s11523-025-01182-0","title":"Amivantamab-Chemotherapy in Non-Small Cell Lung Cancer with EGFR Exon 20 Insertions: Impact of Treatment Crossover and Other Endpoints from the Phase III PAPILLON Study","year":2025,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"Loxo Oncology; Eli Lilly Japan; Chugai Pharmaceutical; Genentech; Grifols; Casen Recordati; Japanese Society of Medical Oncology; Pfizer Japan; Sociedad Española de Oncología Médica; Shionogi; Astellas Pharma; Eisai; Seagen; Lunit; Johnson and Johnson; Les Laboratories Pierre Fabre; Verily Life Sciences; BeiGene; Mirati Therapeutics; Ipsen; Five Prime Therapeutics; Boehringer Ingelheim Japan; Taiho Pharmaceutical; Puma Biotechnology; Regeneron Pharmaceuticals; Yuhan; Daiichi Sankyo Europe; LEO Pharma; Gilead Sciences; Sanofi; Pfizer; Innovent Biologics; Bristol-Myers Squibb; Ono Pharmaceutical; Eli Lilly and Company; AstraZeneca; Amgen; Mesothelioma Applied Research Foundation","keywords":"Lung cancer; Exon; Phases of clinical research; Epidermal growth factor receptor; Cell; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006549551,0.0001995221,0.000460088,0.0001009633,0.00007615855,0.000009723445,0.00005905411,0.00008640447,0.0003152255],"category_scores_gemma":[0.000006133232,0.0001084373,0.00006516978,0.000233285,0.00008844287,0.00003627344,0.00001645187,0.0001082968,0.000001351192],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001198904,"about_ca_system_score_gemma":0.0008405737,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.03191549,"about_ca_topic_score_gemma":0.01142855,"domain_scores_codex":[0.9990793,0.00007598774,0.0002769685,0.0002833158,0.00007425441,0.0002100991],"domain_scores_gemma":[0.9993439,0.0001527449,0.0001274917,0.000260085,0.00005760997,0.00005815984],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.006397783,0.006063522,0.9454127,0.00002310764,0.001937148,0.00005918042,0.01843556,0.0001394648,0.01239446,0.000007494974,0.0006873462,0.008442235],"study_design_scores_gemma":[0.1406376,0.01351514,0.8271316,0.0002354446,0.001920899,0.000006442182,0.004330931,0.0009089683,0.007311663,0.00007797311,0.003694794,0.000228498],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9929682,0.002258912,0.00005383039,0.0005338811,0.0000794918,0.002014905,0.0001627345,0.0000173053,0.001910746],"genre_scores_gemma":[0.9973316,0.0003467789,0.0001893876,0.0007062371,0.00004076278,0.0003887384,0.00004471953,0.00002053224,0.0009312399],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1342398,"threshold_uncertainty_score":0.9745311,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01319791740802506,"score_gpt":0.3870075524723263,"score_spread":0.3738096350643012,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}